Lee Johnson Capital Management LLC Purchases New Stake in Medtronic PLC $MDT

Lee Johnson Capital Management LLC acquired a new position in shares of Medtronic PLC (NYSE:MDT) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 27,303 shares of the medical technology company’s stock, valued at approximately $2,600,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Wynn Capital LLC raised its holdings in shares of Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after purchasing an additional 110 shares during the period. Cape Investment Advisory Inc. increased its position in Medtronic by 3.2% in the second quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock worth $314,000 after buying an additional 113 shares during the last quarter. Gilbert & Cook Inc. raised its stake in shares of Medtronic by 1.9% in the second quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after buying an additional 114 shares during the period. Red Spruce Capital LLC lifted its position in shares of Medtronic by 0.5% during the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock valued at $2,067,000 after buying an additional 118 shares during the last quarter. Finally, Florida Financial Advisors LLC grew its stake in shares of Medtronic by 4.8% during the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock worth $234,000 after acquiring an additional 122 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Up 0.5%

NYSE MDT opened at $96.68 on Wednesday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The stock’s 50-day simple moving average is $97.56 and its two-hundred day simple moving average is $93.92. Medtronic PLC has a twelve month low of $79.38 and a twelve month high of $106.33. The company has a market capitalization of $123.94 billion, a price-to-earnings ratio of 26.06, a PEG ratio of 2.53 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Wall Street Analyst Weigh In

MDT has been the subject of a number of research reports. Daiwa Capital Markets increased their target price on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Citigroup raised their price objective on shares of Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Jefferies Financial Group reissued a “hold” rating and set a $110.00 target price on shares of Medtronic in a report on Wednesday, November 19th. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, December 20th. Finally, The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).